[
  {
    "ts": null,
    "headline": "Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates",
    "summary": "Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=c2cbd924cff7607e4cb0524f36b687c01e5ecad4aeacaa76707dccb1471f0ffe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753824302,
      "headline": "Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates",
      "id": 136130361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=c2cbd924cff7607e4cb0524f36b687c01e5ecad4aeacaa76707dccb1471f0ffe"
    }
  },
  {
    "ts": null,
    "headline": "Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=309682df14f58880e88ee6cee41a700bba82c6cf4650c36c6ef34f0892b18555",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753794903,
      "headline": "Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics",
      "id": 136119610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=309682df14f58880e88ee6cee41a700bba82c6cf4650c36c6ef34f0892b18555"
    }
  }
]